Danielle M. Brander

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema et al. · New England Journal of Medicine · 2018 · 952 citations · Full text

Medicine, Immunology, Oncology +10

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson et al. · Haematologica · 2018 · 452 citations · Full text

Medicine, Oncology, Pharmacology +12

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

John F. Seymour, Shuo Ma, Danielle M. Brander et al. · The Lancet Oncology · 2017 · 327 citations

Life Sciences, Hematology, Immunology +11

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacology +8